Negative effects of individual-based preventive interventions. 2008 SESPAS Report;Los efectos negativos de las intervenciones preventivas basadas en el individuo. Informe SESPAS 2008

Gaceta Sanitaria

Volumn 22, Issue SUPPL. 1, 2008, Pages 205-215

  Márquez Calderón, Soledad ^a  

^a Andalusian Agency for Health Technology Assessment Spain   (Spain)

Author keywords

Adverse effects; Mass screening; Medicalization; Preventive drugs; Preventive health services; Primary prevention; Vaccines

Indexed keywords

EID: 45149085513     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/s0213-9111(08)76094-1     Document Type: Review

References (43)

1. Berg AO, Allan JD. Introducing the Third U.S. Preventive Services Task Force. Am J Prev Med. 2001;20:3-4.
2. US Preventive Services Task Force. Guide to clinical preventive services: report of the US Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins; 1996.
3. Agency for Healthcare Research and Quality [homepage on the internet]. Rockville: The Agency. Quality Guide to Clinical Preventive Services. US Preventive Services Task Force [citado 25 Jul 2007]. Disponible en: http://www.ahrq.gov/clinic/cps3dix.htm
4. Segura-Benedicto A. Inducción sanitaria de los cribados: impacto y consecuencias. Aspectos éticos. Gac Sanit. 2006;20 Supl 1:88-95.
5. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies (II): disentanglement. BMJ. 2003;326:1193-6.
6. Moynihan R, Cassels A. Selling sickness: wow the world's biggest pharmaceutical companies are turning us all into patients. Vancouver: Greystone Books; 2005.
7. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2004.
8. Moynihan R, Health I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886-90.
9. Sackett DL. The arrogance of preventive medicine. CMAJ. 2002;167:363-4.
10. Smith R. The trouble with medical journals. London: Royal Society of Medicine Ltd.; 2006.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
14. American Diabetes Association. Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27 Suppl 1:5-10.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al; and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-72.
16. Saul S. Unease on industry's role in hypertension debate. The New York Times Online [internet]. 2006 May 20 [citado 28 Jun 2007]. Disponible en: http://www.nytimes.com/2006/05/20/business/20hyper.html?ex=1185768000&en= bd2ba66084b9238c&ei=5070
17. Center for Science in the Public Interest [homepage on the Internet]. Washington: The Center [updated 2004 Sept 23]. CSPI Newsroom [citado 6 Ago 2007]. Disponible en: http://www.cspinet.org/integrity/press/200409231.html
18. Monroy-Morcillo A, Márquez-Calderón S, Molina-López T, Domínguez-Camacho JC, Bermúdez-Tamayo C, Escolar-Pujolar A. Tendencias en la prescripción de fármacos preventivos en el distrito de atención primaria de Sevilla (2000-2003). Gac Sanit. 2005;19:471-4.
19. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-8.
20. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291:71-8.
21. US Food and Drug Administration. Center for Devices and Radiological Health [homepage on the Internet]. Whole body scanning. Using computed tomography (CT). Rockville: updated October 12, 2005 [citado 30 Jul 2007]. Disponible en: http://www.fda.gov/cdrh/ct
22. Petticrew MP, Sowden AJ, Lister-Sharp D. False-negative results in screening programs. Medical, psychological, and other implications. Int J Techn Assess Health Care. 2001;17:164-70.
23. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297:953-61.
24. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Almant DG, Schulz K, et al; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-8.
25. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-9.
26. University of California San Diego [homepage on the Internet]. Statins Effects Study. San Diego: updated February 15, 2007 [citado 20 Jun 2007]. Disponible en: http://medicine.ucsd.edu/ses
27. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-105.
28. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-62.
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
30. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-33.
31. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645-50.
32. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-77.
33. Asociación Española para el Estudio de la Menopausia [Internet] [citado 4 Ago 2007]. Disponible en: http://www.aeem.es
34. Márquez S, Meneu R. La medicalización de la vida y sus protagonistas. Gest Clin Sanit. 2003;5:47-53.
35. Sen A. Health: perception versus observation. BMJ. 2002;324:860-1.
36. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs. Clin Med. 2002;2:527-33.
37. Gérvas J, Pérez M. Uso y abuso del poder médico para definir enfermedad y factor de riesgo, en relación con la prevención cuaternaria. Gac Sanit. 2006;20 Supl 3:66-71.
38. Gérvas J. Moderación en la actividad médica preventiva y curativa. Cuatro ejemplos de necesidad de prevención cuaternaria en España. Gac Sanit. 2006;20 Supl 1:127-34.
39. Bailón E, Del Cura I, Gutiérrez B, Landa J, López A, Blasco A. El consenso que no pudo ser. Aten Primaria. 2002;30:341-2.
40. Sociedad Española de Medicina Familiar y Comunitaria. La semFYC considera precipitada la decisión de incluir la vacuna del Virus del Papiloma Humano (VPH) en el calendario vacunal. Noticias semFYC. 2007;34 [revista en Internet] [publicada en octubre de 2007] [citado 7 Dic 2007]. Disponible en: http://server1.semfyc.es/es/noticias/NOTICIASemfyc/octubre307/ opinionA.htm
41. Sociedad Española de Salud Pública y Administración Sanitaria. Declaración de la Junta Directiva de SESPAS sobre la inclusión de una vacuna contra el virus del papiloma humano (VPH) en el calendario oficial [internet] [publicado el 12 de noviembre de 2007] [citado 9 Dic 2007]. Disponible en: http://www.sespas.es/fr_comun.html
42. Fernández de Sanmamed MJ, Marquet R, Reguant M, Zapater F; Grup de Qualitat de la CAMFIC. Malalts de salut? Reflexions al voltant de les noves demandes i les respostes del sistema sanitari [internet]. Barcelona 2006 [citado 16 Dic 2007]. Disponible en: http://www.scmfic.org/grups_treball/altres/ qualitat/Malalts_de_salut%20final.pdf
43. Cohen JJ, Cruess S, Davidson C. 40.1. Alliance between society and medicine. The public's stake in medical professionalism. JAMA. 2007;298:670-3.